Latest Clinical & Research News
Specialty: Endocrinology
Since many patients with diabetes are ineligible for RYGB or decline it, researchers at Brigham and Women’s Hospital developed an orally administered gut barrier coating for improving glucose homeostasis.
Read More...
Researchers in the Brigham’s Division of Pharmacoepidemiology and Pharmacoeconomics, led by Elisabetta Patorno, MD, DrPH, have determined obesity-related International Classification of Disease (ICD) codes accurately identify patients with obesity in claims-based data.
Read More...
Scott Shikora, MD, director of Metabolic and Bariatric Surgery in the Center for Weight Management and Wellness at the Brigham, and colleagues conclude one-stage laparoscopic adjustable gastric band to sleeve gastrectomy conversion is safe and effective when performed by experienced surgeons.
Read More...
Research at Brigham and Women’s Hospital explored how laparoscopic sleeve gastrectomy improves the systemic inflammatory profile and found pronounced improvement in immune cell composition, function and metabolism, as measured by both biomarkers and gene expression, as soon as three months after the procedure.
Read More...
By studying how cells from healthy normal weight and overweight participants broke down carbohydrates in real time, researchers including Brigham obesity medicine specialists Nawfal W. Istfan, MD, PhD, and Caroline M. Apovian, MD, have uncovered clues about what triggers metabolic distress.
Read More...
Jose R. Romero, PhD, and colleagues have now used a prevous model of patients with rs2540923 to show that striatin serves a protective role in the hemostatic system, which may be reduced in humans with striatin risk alleles.
Read More...
Gordon H. Williams, MD, senior physician in the Division of Endocrinology, Diabetes and Hypertension at the Brigham, Shadi K. Gholami, PhD, research fellow, and colleagues have expanded on their earlier work to determine if biological sex affects the production of aldosterone levels.
Read More...
Ellen W. Seely, MD, director of clinical research in the Endocrinology, Diabetes and Hypertension Division, discusses the Brigham’s proactive approach to mitigating the impact of gestational diabetes on mothers, fetuses and newborn babies.
Read More...
Practice guidelines recommend considering sodium–glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients who have both diabetes and atherosclerotic cardiovascular disease (CVD). The choice between the drug classes is left to the physician, except that SGLT2 inhibitors are advised for patients with a history of heart failure.
Brigham and Women’s Hospital’s Division of Endocrinology, Diabetes and Hypertension cares for patients with a wide range of hormonal and other related disorders, including diabetes, hypertension and thyroid disease. Division Chief Ursula B. Kaiser, MD, recently discussed some of her group’s accomplishments and how the COVID-19 pandemic has affected physicians and other health care providers in the division.